Communicate with Supplier? Supplier
Kelly Ms. Kelly
What can I do for you?
+8613375313165
Chat Now
Chat Now Contact Supplier

 Shandong Haohong Biotechnology Co., Ltd.

All
  • All
  • Title
All
  • All
  • Title
HomeProductsActive Pharmaceutical Ingredient(API)Regorafenib Hydrate

Regorafenib Hydrate (Total 2 Products)

Product categories of Regorafenib Hydrate, we are specialized manufacturers from China, Regorafenib Monohydrate CAS 1019206-88-2, Regorafenib Hydrate suppliers/factory, wholesale high-quality products of Regorafenib Hydrate R & D and manufacturing, we have the perfect after-sales service and technical support. Look forward to your cooperation!
Top Quality Best Price Regorafenib monohydrate (BAY 73-4506)

Brand: HAOHONG

Packaging: PE BAG+Aluminum foil bag+FIBRE DRUM

Supply Ability: 30MT/MONTH

Product Name 4 4 4 chloro 3 trifluoromethyl phenyl carbamoylamino 3 fluorophenoxy N methylpyridine 2 carboxamide hydrate Stivarga MGN125FS9D Regorafenib hydrate 4 4 4 chloro 3 trifluoromethyl phenyl carbamoyl amino 3 fluorophenoxy N methylpyridine 2...
Pharmaceutical Raw Material regorafenib hydrate

Brand: HAOHONG

Packaging: PE BAG+Aluminum foil bag+FIBRE DRUM

Supply Ability: 30MT/MONTH

Product Name 4 4 4 chloro 3 trifluoromethyl phenyl carbamoylamino 3 fluorophenoxy N methylpyridine 2 carboxamide hydrate Stivarga MGN125FS9D Regorafenib hydrate 4 4 4 chloro 3 trifluoromethyl phenyl carbamoyl amino 3 fluorophenoxy N methylpyridine 2...

China Regorafenib Hydrate Suppliers

Regorafenib Hydrate is a hydrate that is the monohydrate form of anhydrous regorafenib. Used for for the treatment of metastatic colorectal cancer in patients who have previously received chemotherapy, anti-EGFR or anti-VEGF therapy. It has a role as an antineoplastic agent, a tyrosine kinase inhibitor and a hepatotoxic agent. It contains a regorafenib.

Regorafenib is an oral multi-kinase inhibitor that is used in the therapy of refractory metastatic colorectal cancer, hepatocellular carcinoma and gastrointestinal stromal tumor. Regorafenib has been associated with frequent serum aminotransferase elevations during therapy and with rare, but sometimes severe and even fatal instances of clinically apparent liver injury.

Regorafenib is a pyridinecarboxamide obtained by condensation of 4-[4-({[4-chloro-3-(trifluoromethyl)phenyl]carbamoyl}amino)-3-fluorophenoxy]pyridine-2-carboxylic acid with methylamine. Used for for the treatment of metastatic colorectal cancer in patients who have previously received chemotherapy, anti-EGFR or anti-VEGF therapy. It has a role as an antineoplastic agent, a tyrosine kinase inhibitor and a hepatotoxic agent. It is an aromatic ether, a pyridinecarboxamide, a member of monochlorobenzenes, a member of (trifluoromethyl)benzenes, a member of monofluorobenzenes and a member of phenylureas.

Home

Product

Whatsapp

About Us

Inquiry